Kryptos Biotechnologies Raises $10M in Series A Funding for Clinical Study of Respiratory Combo Tests

Kryptos Biotechnologies' Series A Funding

Key Highlights:

• Series A Funding: Raised $10 million in Series A funding.
• Investor: Funding led by Osang Healthcare.
• Technology: Utilizes photothermal heating, using light to generate heat and control temperature for molecular diagnostic devices and life science instruments.
• Clinical Study: Funds will be used to advance the clinical study of respiratory combo tests, aiming for FDA approval by 2025.

Kryptos Biotechnologies' Target Market

• Healthcare Providers: Clinicians and healthcare professionals seeking efficient and accurate molecular diagnostic systems.
• Point-of-Care Testing: Facilities and organizations looking for point-of-care molecular diagnostic systems that provide quick results with high accuracy.
• Life Science Research: Research institutions and laboratories requiring precise temperature control for molecular biology experiments and assays.

What Kryptos Biotechnologies Needs to Buy

• Manufacturing and Distribution Partners: Partnerships with companies experienced in manufacturing and distributing medical devices and diagnostic systems.
• Regulatory Compliance Services: Assistance in navigating FDA approval processes and ensuring compliance with regulatory requirements.
• Research and Development Collaboration: Collaborations with research institutions and technology partners to further enhance their photothermal heating technology and develop new applications.